4-OXO –N (4- Hydroxyphenyl) Retinamide derivatives as therapeutic agents for the treatment of cancer


-Istituto Nazionale Tumori-

Patent relating to a new derivative of vitamin A which combines excellent antitumor efficacy with excellent tolerability.

4-OXO –N

It is a new derivative of vitamin A (sodium 4-oxo-4- HPR) that combines excellent anticancer efficacy with excellent tolerability.

Its peculiarity consists in killing cancer cells through two independent mechanisms of action, allowing to effectively counteract the pharmacological resistance of different tumors, and allowing an enhancement of the activity of other chemotherapeutics such as platinum salts and taxanes, thus reducing the effective dose and therefore the toxicity.

In vitro and in vivo administration in several tumor models (ovarian, breast, neuroblastoma, lymphoma, mesothelioma) showed significant cytotoxic activity, inhibiting tumour growth and increasing survival, both in monotherapy and in synergistic combination with cisplatin and paclitaxel.

Due to its promising features, the project has been successful to the point of obtaining substantial funding with a co-development contract in 2017.

Patent (WO2016042010) – filed in 2014, jointly owned (70% INT- 30 % UNIMI)

Autore del post:

Skip to content